Is One SGLT2 (Or GLP-1) Just Like Another for Cardiac Benefit?
Medscape,
Hello. I'm Dr Charles Vega, and I am a clinical professor of family medicine at the University of California at Irvine.
Hello. I'm Dr Charles Vega, and I am a clinical professor of family medicine at the University of California at Irvine.
SGLT2 inhibitors were first approved in 2013 for the treatment of type 2 diabetes.
NEW ORLEANS – Dapagliflozin markedly reduces the risks of both major adverse cardiovascular events and heart failure…
NEW ORLEANS – Dapagliflozin markedly reduces the risks of both major adverse cardiovascular events and heart failure…